News | Pacemakers | May 24, 2018

Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block

Study finds significant advantages with permanent pacing versus an implantable cardiac monitor for particular patient group

Permanent Pacing Effective for Older Patients With Syncope and Bifascicular Block

May 24, 2018 — Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist. A new study tested whether a strategy of empiric permanent pacing (PM) reduces major adverse events more effectively than acting on the results of an implantable cardiac monitor (ICM). Results of the study were presented at Heart Rhythm 2018, the 39th annual scientific sessions of the Heart Rhythm Society (HRS), May 9-12 in Boston.

In a multinational, randomized, pragmatic trial, 56 subjects under 50 years old with bifascicular block, preserved left ventricular function, and less than or equal to one syncope in the preceding year, received PM and 59 received an ICM. The primary outcome measure was a composite of Major Adverse Study-Related Events (MASRE), comprised of death, syncope, symptomatic bradycardia, asymptomatic actionable bradycardia and device complications.

The PM and ICM groups were similar in age, sex, lifetime syncopes, syncope in prior year, duration of symptoms, no prodrome and baseline systolic BP. Forty patients had left bundle branch block and 75 had right bundle branch block and a left hemiblock. Patients were followed for a median 30 months, and 21 exited the study — eight patients died, six withdrew consent after 2 years, four withdrew due to cancer and three due to dementia.

PM effectively prevented the primary outcome with end study MASRE-free survivals in PM (63 percent) and ICM (22 percent) group (p<0.001). The proportions of patients with syncope were similar in PM and ICM groups (27 vs 31 percent, p=0.50, Wilcoxon). Fully 35 out of 59 ICM patients (59 percent) crossed over to PM. There were five pacemaker complications requiring reintervention.

The researchers concluded that permanent pacing compared to ICM is a preferred strategy in elderly patients with few but recent syncopal spells and bifascicular block. This is driven by the high proportion of mildly symptomatic bradycardias detected on ICMs leading to pacemaker insertion.

For more information: www.hrssessions.org

Read more about HRS 2018 late-breaking studies


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now